A	O
Mapping	O
of	O
Drug	O
Space	O
from	O
the	O
Viewpoint	O
of	O
Small	O
Molecule	O
Metabolism	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
JCA	O
MJK	O
OGW	O
PCB	O
.	O

Performed	O
the	O
experiments	O
:	O
JCA	O
MJK	O
LB	O
.	O

Analyzed	O
the	O
data	O
:	O
JCA	O
OGW	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
MJK	O
D	O
-	O
SL	O
HFC	O
.	O

Wrote	O
the	O
paper	O
:	O
JCA	O
PCB	O
.	O

Small	O
molecule	O
drugs	O
target	O
many	O
core	O
metabolic	O
enzymes	O
in	O
humans	B-OG
and	O
pathogens	O
,	O
often	O
mimicking	O
endogenous	O
ligands	O
.	O

The	O
effects	O
may	O
be	O
therapeutic	O
or	O
toxic	O
,	O
but	O
are	O
frequently	O
unexpected	O
.	O

A	O
large	O
-	O
scale	O
mapping	O
of	O
the	O
intersection	O
between	O
drugs	O
and	O
metabolism	O
is	O
needed	O
to	O
better	O
guide	O
drug	O
discovery	O
.	O

To	O
map	O
the	O
intersection	O
between	O
drugs	O
and	O
metabolism	O
,	O
we	O
have	O
grouped	O
drugs	O
and	O
metabolites	O
by	O
their	O
associated	O
targets	O
and	O
enzymes	O
using	O
ligand	O
-	O
based	O
set	O
signatures	O
created	O
to	O
quantify	O
their	O
degree	O
of	O
similarity	O
in	O
chemical	O
space	O
.	O

The	O
results	O
reveal	O
the	O
chemical	O
space	O
that	O
has	O
been	O
explored	O
for	O
metabolic	O
targets	O
,	O
where	O
successful	O
drugs	O
have	O
been	O
found	O
,	O
and	O
what	O
novel	O
territory	O
remains	O
.	O

To	O
aid	O
other	O
researchers	O
in	O
their	O
drug	O
discovery	O
efforts	O
,	O
we	O
have	O
created	O
an	O
online	O
resource	O
of	O
interactive	O
maps	O
linking	O
drugs	O
to	O
metabolism	O
.	O

These	O
maps	O
predict	O
the	O
“	O
effect	O
space	O
”	O
comprising	O
likely	O
target	O
enzymes	O
for	O
each	O
of	O
the	O
246	O
MDDR	O
drug	O
classes	O
in	O
humans	B-OG
.	O

The	O
online	O
resource	O
also	O
provides	O
species	O
-	O
specific	O
interactive	O
drug	O
-	O
metabolism	O
maps	O
for	O
each	O
of	O
the	O
385	O
model	O
organisms	O
and	O
pathogens	O
in	O
the	O
BioCyc	O
database	O
collection	O
.	O

Chemical	O
similarity	O
links	O
between	O
drugs	O
and	O
metabolites	O
predict	O
potential	O
toxicity	O
,	O
suggest	O
routes	O
of	O
metabolism	O
,	O
and	O
reveal	O
drug	O
polypharmacology	O
.	O

The	O
metabolic	O
maps	O
enable	O
interactive	O
navigation	O
of	O
the	O
vast	O
biological	O
data	O
on	O
potential	O
metabolic	O
drug	O
targets	O
and	O
the	O
drug	O
chemistry	O
currently	O
available	O
to	O
prosecute	O
those	O
targets	O
.	O

Thus	O
,	O
this	O
work	O
provides	O
a	O
large	O
-	O
scale	O
approach	O
to	O
ligand	O
-	O
based	O
prediction	O
of	O
drug	O
action	O
in	O
small	O
molecule	O
metabolism	O
.	O

Author	O
Summary	O

All	O
humans	B-OG
,	O
plants	B-OG
,	O
and	O
animals	B-OG
use	O
enzymes	O
to	O
metabolize	O
food	O
for	O
energy	O
,	O
build	O
and	O
maintain	O
the	O
body	O
,	O
and	O
get	O
rid	O
of	O
toxins	O
.	O

Drugs	O
used	O
to	O
clear	O
infections	B-DS
or	O
cure	O
cancer	B-DS
often	O
target	O
enzymes	O
in	O
bacteria	B-OG
or	O
cancer	B-DS
cells	O
,	O
but	O
the	O
drugs	O
can	O
interfere	O
with	O
the	O
proper	O
function	O
of	O
human	B-OG
enzymes	O
as	O
well	O
.	O

Recent	O
studies	O
have	O
mapped	O
drugs	O
to	O
enzymes	O
and	O
many	O
other	O
targets	O
in	O
humans	B-OG
and	O
other	O
organisms	O
,	O
but	O
have	O
not	O
focused	O
on	O
metabolism	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
a	O
new	O
method	O
to	O
predict	O
what	O
enzymes	O
drugs	O
might	O
affect	O
based	O
on	O
the	O
chemical	O
similarity	O
between	O
classes	O
of	O
drugs	O
and	O
the	O
natural	O
chemicals	O
used	O
by	O
enzymes	O
.	O

We	O
have	O
applied	O
the	O
method	O
to	O
246	O
known	O
drug	O
classes	O
and	O
a	O
collection	O
of	O
385	O
organisms	O
(	O
including	O
65	O
National	O
Institutes	O
of	O
Health	O
Priority	O
Pathogens	O
)	O
to	O
create	O
maps	O
of	O
potential	O
drug	O
action	O
in	O
metabolism	O
.	O

We	O
also	O
show	O
how	O
the	O
predicted	O
connections	O
can	O
be	O
used	O
to	O
find	O
new	O
ways	O
to	O
kill	O
pathogens	O
and	O
to	O
avoid	O
unintentionally	O
interfering	O
with	O
human	B-OG
enzymes	O
.	O

Introduction	O

Drug	O
developers	O
have	O
long	O
mined	O
small	O
molecule	O
metabolism	O
for	O
new	O
drug	O
targets	O
and	O
chemical	O
strategies	O
for	O
inhibition	O
.	O

The	O
approach	O
leverages	O
the	O
“	O
chemical	O
similarity	O
principle	O
”	O
[	O
1	O
]	O
which	O
states	O
that	O
similar	O
molecules	O
likely	O
have	O
similar	O
properties	O
.	O

Applied	O
to	O
small	O
molecule	O
metabolism	O
,	O
this	O
principle	O
has	O
motivated	O
the	O
search	O
for	O
enzyme	O
inhibitors	O
chemically	O
similar	O
to	O
their	O
endogenous	O
substrates	O
.	O

The	O
approach	O
has	O
yielded	O
many	O
successes	O
,	O
including	O
antimetabolites	O
such	O
as	O
the	O
folate	O
derivatives	O
used	O
in	O
cancer	B-DS
therapy	O
and	O
the	O
nucleoside	O
analog	O
pro	O
-	O
drugs	O
used	O
for	O
antiviral	O
therapy	O
.	O

However	O
,	O
drug	O
discovery	O
efforts	O
also	O
frequently	O
falter	O
due	O
to	O
unacceptable	O
metabolic	O
side	O
-	O
effect	O
profiles	O
or	O
incomplete	O
genomic	O
information	O
for	O
poorly	O
characterized	O
pathogens	O
[	O
2	O
]–[	O
4	O
].	O

With	O
the	O
recent	O
availability	O
of	O
large	O
datasets	O
of	O
drugs	O
and	O
drug	O
-	O
like	O
molecules	O
,	O
computational	O
profiling	O
of	O
small	O
molecules	O
has	O
been	O
performed	O
to	O
create	O
global	O
maps	O
of	O
pharmacological	O
activity	O
.	O

This	O
in	O
turn	O
provides	O
a	O
larger	O
context	O
for	O
evaluation	O
of	O
metabolic	O
targets	O
.	O

For	O
example	O
,	O
Paolini	O
et	O
al	O
.	O
[	O
5	O
]	O
identified	O
727	O
human	B-OG
drug	O
targets	O
associated	O
with	O
ligands	O
exhibiting	O
potency	O
at	O
concentrations	O
below	O
10	O
µM	O
,	O
thereby	O
creating	O
a	O
polypharmacology	O
interaction	O
network	O
organized	O
by	O
the	O
similarity	O
between	O
ligand	O
binding	O
profiles	O
.	O

Keiser	O
et	O
al	O
.	O
[	O
6	O
]	O
organized	O
known	O
drug	O
targets	O
into	O
biologically	O
sensible	O
clusters	O
based	O
solely	O
upon	O
the	O
bond	O
topology	O
of	O
65	O
,	O
000	O
biologically	O
active	O
ligands	O
.	O

The	O
results	O
revealed	O
new	O
and	O
unexpected	O
pharmacological	O
relationships	O
,	O
three	O
of	O
which	O
involved	O
GPCRs	B-GP
and	O
their	O
predicted	O
ligands	O
that	O
were	O
subsequently	O
confirmed	O
in	O
vitro	O
.	O

Cleves	O
et	O
al	O
.	O
[	O
7	O
]	O
also	O
rationalized	O
several	O
known	O
drug	O
side	O
effects	O
and	O
drug	O
-	O
drug	O
interactions	O
based	O
upon	O
three	O
-	O
dimensional	O
modeling	O
of	O
979	O
approved	O
drugs	O
.	O

However	O
,	O
despite	O
the	O
clear	O
rationale	O
and	O
past	O
successes	O
in	O
applying	O
ligand	O
-	O
based	O
approaches	O
to	O
drug	O
discovery	O
,	O
global	O
mapping	O
between	O
drugs	O
and	O
small	O
molecule	O
metabolism	O
,	O
the	O
goal	O
of	O
this	O
study	O
,	O
has	O
been	O
hindered	O
by	O
both	O
methodological	O
challenges	O
and	O
incomplete	O
genomic	O
information	O
.	O

The	O
relatively	O
recent	O
availability	O
of	O
metabolomes	O
for	O
numerous	O
organisms	O
allows	O
a	O
fresh	O
look	O
on	O
a	O
large	O
scale	O
[	O
8	O
]–[	O
13	O
].	O

In	O
this	O
work	O
,	O
we	O
link	O
the	O
chemistry	O
of	O
drugs	O
to	O
the	O
chemistry	O
of	O
small	O
molecule	O
metabolites	O
to	O
investigate	O
the	O
intersection	O
between	O
small	O
molecule	O
metabolism	O
and	O
drugs	O
.	O

The	O
Similarity	O
Ensemble	O
Approach	O
(	O
SEA	O
)	O
[	O
6	O
]	O
was	O
used	O
to	O
link	O
metabolic	O
reactions	O
and	O
drug	O
classes	O
by	O
their	O
chemical	O
similarity	O
,	O
measured	O
by	O
comparing	O
bond	O
topology	O
patterns	O
between	O
sets	O
of	O
molecules	O
.	O

Two	O
types	O
of	O
molecule	O
sets	O
are	O
used	O
in	O
this	O
work	O
.	O

The	O
first	O
comprises	O
drug	O
-	O
like	O
molecules	O
known	O
to	O
act	O
at	O
a	O
specific	O
protein	O
target	O
,	O
and	O
the	O
second	O
comprises	O
the	O
known	O
substrates	O
and	O
products	O
of	O
an	O
enzymatic	O
reaction	O
.	O

While	O
this	O
approach	O
is	O
complementary	O
to	O
target	O
and	O
disease	O
focused	O
methods	O
[	O
5	O
],	O
[	O
14	O
]–[	O
23	O
],	O
neither	O
protein	O
structure	O
nor	O
sequence	O
information	O
is	O
used	O
in	O
the	O
comparisons	O
.	O

Thus	O
,	O
these	O
links	O
provide	O
an	O
orthogonal	O
view	O
of	O
metabolism	O
based	O
only	O
upon	O
the	O
chemical	O
similarity	O
between	O
existing	O
drug	O
classes	O
and	O
endogenous	O
metabolites	O
.	O

To	O
provide	O
the	O
results	O
in	O
the	O
context	O
of	O
metabolism	O
,	O
drug	O
“	O
effect	O
-	O
space	O
”	O
maps	O
were	O
also	O
created	O
.	O

For	O
each	O
of	O
the	O
246	O
drug	O
classes	O
investigated	O
in	O
this	O
work	O
,	O
effect	O
-	O
space	O
maps	O
enable	O
visualization	O
of	O
the	O
chemical	O
similarities	O
between	O
drugs	O
and	O
metabolites	O
painted	O
onto	O
human	B-OG
metabolic	O
pathways	O
,	O
allowing	O
a	O
unique	O
assessment	O
of	O
potential	O
drug	O
action	O
in	O
humans	B-OG
.	O

In	O
addition	O
,	O
to	O
aid	O
target	O
discovery	O
in	O
pathogens	O
,	O
385	O
species	O
-	O
specific	O
effect	O
-	O
space	O
maps	O
were	O
created	O
to	O
show	O
the	O
predicted	O
effect	O
-	O
space	O
of	O
currently	O
marketed	O
drugs	O
,	O
painted	O
onto	O
metabolic	O
pathways	O
representing	O
target	O
reactions	O
in	O
model	O
organisms	O
and	O
pathogens	O
.	O

Examples	O
of	O
these	O
maps	O
are	O
provided	O
below	O
and	O
their	O
applications	O
in	O
predicting	O
drug	O
action	O
,	O
toxicity	O
,	O
and	O
routes	O
of	O
metabolism	O
are	O
discussed	O
.	O

To	O
enable	O
facile	O
exploration	O
of	O
the	O
drug	O
-	O
metabolite	O
links	O
established	O
by	O
this	O
analysis	O
,	O
interactive	O
versions	O
of	O
both	O
sets	O
of	O
maps	O
are	O
available	O
at	O
http	O
://	O
sea	O
.	O
docking	O
.	O
org	O
/	O
metabolism	O
.	O

Finally	O
,	O
using	O
methicillin	B-OG
-	I-OG
resistant	I-OG
Staphylococcus	I-OG
aureus	I-OG
(	O
MRSA	B-OG
),	O
a	O
major	O
pathogen	O
causing	O
both	O
hospital	O
-	O
and	O
community	B-DS
-	I-DS
acquired	I-DS
infections	I-DS
that	O
is	O
resistant	O
to	O
at	O
least	O
one	O
of	O
the	O
antibiotics	O
most	O
commonly	O
used	O
for	O
treatment	O
[	O
24	O
]–[	O
28	O
]	O
as	O
an	O
example	O
,	O
we	O
show	O
by	O
retrospective	O
analysis	O
the	O
use	O
of	O
species	O
-	O
specific	O
maps	O
for	O
discovery	O
and	O
evaluation	O
of	O
drug	O
targets	O
.	O

This	O
also	O
illustrates	O
how	O
additional	O
types	O
of	O
biological	O
information	O
can	O
be	O
incorporated	O
to	O
enhance	O
the	O
value	O
of	O
these	O
analyses	O
.	O

Results	O

Drug	O
-	O
metabolite	O
links	O
reproduce	O
known	O
drug	O
-	O
target	O
interactions	O

To	O
evaluate	O
the	O
chemical	O
similarity	O
between	O
drug	O
classes	O
and	O
metabolic	O
reactions	O
,	O
links	O
between	O
sets	O
of	O
metabolic	O
ligands	O
and	O
sets	O
of	O
drugs	O
were	O
generated	O
according	O
to	O
SEA	O
(	O
Figure	O
1	O
)	O
[	O
6	O
].	O

The	O
similarity	O
metric	O
consists	O
of	O
a	O
descriptor	O
,	O
represented	O
by	O
standard	O
two	O
-	O
dimensional	O
topological	O
fingerprints	O
,	O
and	O
a	O
similarity	O
criterion	O
,	O
the	O
Tanimoto	O
coefficient	O
(	O
Tc	O
).	O

Expectation	O
(	O
E	O
)	O
values	O
were	O
calculated	O
for	O
each	O
set	O
pair	O
by	O
comparing	O
the	O
raw	O
scores	O
to	O
a	O
background	O
distribution	O
generated	O
using	O
sets	O
of	O
randomly	O
selected	O
molecules	O
(	O
see	O
Methods	O
for	O
further	O
details	O
).	O

To	O
represent	O
metabolic	O
ligand	O
sets	O
,	O
the	O
MetaCyc	O
database	O
,	O
which	O
includes	O
enzymes	O
from	O
more	O
than	O
900	O
different	O
organisms	O
catalyzing	O
over	O
6	O
,	O
000	O
reactions	O
,	O
was	O
used	O
[	O
12	O
].	O

The	O
substrates	O
and	O
products	O
of	O
each	O
enzymatic	O
reaction	O
were	O
combined	O
to	O
form	O
a	O
reaction	O
set	O
,	O
each	O
of	O
which	O
was	O
required	O
to	O
contain	O
at	O
least	O
two	O
unique	O
compounds	O
(	O
Datasets	O
S1	O
and	O
S2	O
).	O

Ubiquitous	O
molecules	O
called	O
common	O
carriers	O
,	O
which	O
frequently	O
play	O
critical	O
roles	O
in	O
reaction	O
chemistry	O
but	O
do	O
not	O
distinguish	O
the	O
function	O
of	O
a	O
specific	O
enzyme	O
,	O
were	O
removed	O
,	O
leaving	O
a	O
total	O
of	O
5	O
,	O
056	O
reactions	O
involving	O
4	O
,	O
998	O
unique	O
compounds	O
.	O

To	O
represent	O
drugs	O
,	O
a	O
subset	O
of	O
246	O
targets	O
of	O
the	O
MDL	O
Drug	O
Data	O
Report	O
(	O
MDDR	O
)	O
collection	O
,	O
which	O
annotates	O
ligands	O
according	O
to	O
the	O
targets	O
they	O
modulate	O
,	O
was	O
used	O
(	O
Datasets	O
S3	O
and	O
S4	O
)	O
[	O
30	O
].	O

These	O
sets	O
contain	O
65	O
,	O
241	O
unique	O
ligands	O
with	O
a	O
median	O
and	O
mean	O
of	O
124	O
and	O
289	O
ligands	O
per	O
target	O
,	O
respectively	O
.	O

Overall	O
,	O
246	O
drug	O
versus	O
5	O
,	O
056	O
reaction	O
set	O
comparisons	O
involving	O
1	O
.	O
39	O
×	O
109	O
pairwise	O
comparisons	O
were	O
made	O
.	O

Similarity	O
Ensemble	O
Approach	O
(	O
SEA	O
).	O

SEA	O
compares	O
groups	O
of	O
ligands	O
based	O
upon	O
bond	O
topology	O
.	O

Example	O
ligand	O
sets	O
include	O
the	O
thymidylate	B-GP
synthase	I-GP
reaction	O
set	O
,	O
composed	O
of	O
the	O
reaction	O
substrates	O
and	O
products	O
,	O
and	O
the	O
nucleotide	O
reverse	B-GP
transcriptase	I-GP
inhibitor	O
(	O
NRTI	O
)	O
drug	O
set	O
,	O
which	O
includes	O
known	O
inhibitors	O
of	O
the	O
nucleoside	O
reverse	B-GP
transcriptase	I-GP
enzyme	O
.	O

Fingerprints	O
representing	O
the	O
bond	O
topology	O
of	O
each	O
molecule	O
are	O
generated	O
.	O

Raw	O
scores	O
between	O
sets	O
are	O
calculated	O
based	O
upon	O
Tanimoto	O
coefficients	O
between	O
fingerprints	O
for	O
all	O
molecule	O
pairs	O
.	O

Finally	O
,	O
the	O
raw	O
scores	O
are	O
compared	O
to	O
a	O
background	O
distribution	O
to	O
determine	O
the	O
expectation	O
value	O
(	O
E	O
)	O
representing	O
the	O
chemical	O
similarity	O
between	O
sets	O
.	O

See	O
Methods	O
for	O
further	O
details	O
.	O

Although	O
drugs	O
and	O
metabolites	O
typically	O
differ	O
in	O
their	O
physiochemical	O
properties	O
,	O
significant	O
and	O
specific	O
similarity	O
links	O
nonetheless	O
emerged	O
.	O

Using	O
SEA	O
at	O
an	O
expectation	O
value	O
cutoff	O
of	O
E	O
=	O
1	O
.	O
0	O
×	O
10	O
−	O
10	O
,	O
a	O
previously	O
reported	O
cutoff	O
for	O
significance	O
[	O
6	O
],	O
54	O
%	O
(	O
132	O
of	O
246	O
)	O
of	O
drug	O
sets	O
link	O
to	O
an	O
average	O
of	O
43	O
.	O
7	O
(	O
median	O
=	O
10	O
)	O
or	O
0	O
.	O
9	O
%	O
of	O
metabolic	O
reactions	O
.	O

None	O
of	O
the	O
remaining	O
46	O
%	O
(	O
114	O
of	O
246	O
)	O
of	O
drug	O
sets	O
link	O
to	O
any	O
metabolic	O
reaction	O
sets	O
.	O

For	O
instance	O
,	O
while	O
the	O
α	B-GP
-	I-GP
glucosidase	I-GP
drug	O
set	O
links	O
to	O
the	O
α	B-GP
-	I-GP
glucosidase	I-GP
reaction	O
(	O
E	O
=	O
1	O
.	O
00	O
×	O
10	O
−	O
51	O
),	O
the	O
thrombin	B-GP
inhibitor	O
drug	O
set	O
does	O
not	O
link	O
significantly	O
with	O
any	O
metabolic	O
reaction	O
.	O

The	O
thrombin	B-GP
inhibitor	O
drug	O
set	O
targets	O
the	O
serine	B-GP
protease	I-GP
thrombin	B-GP
,	O
which	O
does	O
not	O
participate	O
in	O
small	O
molecule	O
metabolism	O
,	O
but	O
rather	O
plays	O
a	O
role	O
in	O
the	O
coagulation	O
signaling	O
cascade	O
.	O

Likewise	O
,	O
40	O
%	O
(	O
2	O
,	O
044	O
of	O
5	O
,	O
056	O
)	O
of	O
metabolic	O
reactions	O
hit	O
an	O
average	O
of	O
2	O
.	O
8	O
(	O
median	O
=	O
2	O
)	O
or	O
1	O
.	O
1	O
%	O
of	O
drug	O
sets	O
at	O
expectation	O
value	O
E	O
=	O
1	O
.	O
0	O
×	O
10	O
−	O
10	O
or	O
better	O
.	O

For	O
instance	O
,	O
the	O
metabolite	O
set	O
for	O
retinal	B-GP
dehydrogenase	I-GP
reaction	O
set	O
links	O
,	O
as	O
expected	O
,	O
to	O
the	O
retinoid	O
drugs	O
at	O
E	O
=	O
3	O
.	O
05	O
×	O
E	O
−	O
98	O
,	O
but	O
the	O
valine	B-GP
decarboxylase	I-GP
reaction	O
,	O
which	O
is	O
not	O
an	O
MDDR	O
drug	O
target	O
,	O
does	O
not	O
link	O
significantly	O
to	O
any	O
drug	O
sets	O
.	O

These	O
strikingly	O
similar	O
results	O
suggest	O
both	O
broad	O
coverage	O
(	O
54	O
%	O
of	O
drug	O
sets	O
and	O
40	O
%	O
of	O
metabolite	O
sets	O
)	O
and	O
specificity	O
(	O
single	O
sets	O
link	O
to	O
just	O
0	O
.	O
9	O
%	O
of	O
metabolite	O
sets	O
and	O
1	O
.	O
1	O
%	O
of	O
drug	O
sets	O
,	O
respectively	O
).	O

For	O
full	O
results	O
,	O
see	O
Dataset	O
S5	O
.	O

To	O
determine	O
the	O
utility	O
of	O
the	O
method	O
for	O
recovery	O
of	O
known	O
drug	O
-	O
target	O
interactions	O
,	O
it	O
was	O
hypothesized	O
that	O
chemical	O
similarity	O
between	O
MetaCyc	O
reaction	O
sets	O
and	O
corresponding	O
MDDR	O
drug	O
sets	O
could	O
specifically	O
recover	O
the	O
known	O
drug	O
-	O
target	O
interactions	O
.	O

The	O
246	O
MDDR	O
drug	O
set	O
targets	O
include	O
62	O
enzymes	O
that	O
could	O
be	O
mapped	O
to	O
MetaCyc	O
via	O
the	O
Enzyme	O
Commission	O
(	O
EC	O
)	O
number	O
[	O
31	O
]	O
describing	O
the	O
overall	O
reaction	O
catalyzed	O
[	O
32	O
].	O

The	O
results	O
show	O
that	O
all	O
62	O
reaction	O
sets	O
for	O
these	O
targets	O
link	O
to	O
at	O
least	O
one	O
MDDR	O
drug	O
set	O
.	O

The	O
majority	O
of	O
best	O
hits	O
(	O
42	O
out	O
of	O
62	O
)	O
were	O
found	O
at	O
expectation	O
values	O
of	O
E	O
=	O
1	O
.	O
0	O
×	O
10	O
−	O
10	O
or	O
better	O
(	O
Table	O
1	O
).	O

At	O
expectation	O
values	O
better	O
than	O
E	O
=	O
1	O
.	O
0	O
×	O
10	O
−	O
25	O
,	O
61	O
%	O
(	O
19	O
of	O
31	O
)	O
of	O
best	O
hits	O
recover	O
either	O
the	O
specific	O
known	O
target	O
or	O
another	O
enzyme	O
in	O
the	O
same	O
pathway	O
.	O

Examples	O
of	O
specific	O
compounds	O
linked	O
by	O
this	O
analysis	O
are	O
given	O
in	O
Figure	O
2	O
for	O
a	O
selected	O
group	O
of	O
these	O
best	O
-	O
scoring	O
hits	O
.	O

Selected	O
best	O
hits	O
between	O
MetaCyc	O
reaction	O
sets	O
and	O
MDDR	O
drug	O
sets	O
.	O

Metabolic	O
enzyme	O
targets	O
and	O
their	O
best	O
links	O
to	O
MDDR	O
.	O

Enzyme	O
Targeta	O

EC	O
#	O

Best	O
Hit	O
MDDR	O
Drug	O
Set	O

Best	O
Hit	O
E	O
-	O
value	O

Adenosine	O
kinase	B-GP

2	O
.	O
7	O
.	O
1	O
.	O
20	O

S	B-GP
-	I-GP
Adenosyl	I-GP
-	I-GP
L	I-GP
-	I-GP
Homocysteine	I-GP
Hydrolase	I-GP
Inhibitor	O

4	O
.	O
38E	O
-	O
288	O

Adenosylmethionine	O
decarboxylase	O

4	O
.	O
1	O
.	O
1	O
.	O
50	O

S	B-GP
-	I-GP
Adenosyl	I-GP
-	I-GP
L	I-GP
-	I-GP
Homocysteine	I-GP
Hydrolase	I-GP
Inhibitor	O

2	O
.	O
71E	O
-	O
216	O

Thromboxane	O
-	O
A	O
synthase	O

5	O
.	O
3	O
.	O
99	O
.	O
5	O

Prostaglandin	O

1	O
.	O
66E	O
-	O
204	O

Adenosylhomocysteinase	O

3	O
.	O
3	O
.	O
1	O
.	O
1	O

S	B-GP
-	I-GP
Adenosyl	I-GP
-	I-GP
L	I-GP
-	I-GP
Homocysteine	I-GP
Hydrolase	I-GP
Inhibitor	O

4	O
.	O
73E	O
-	O
203	O

Adenosine	B-GP
deaminase	I-GP

3	O
.	O
5	O
.	O
4	O
.	O
4	O

Adenosine	O
(	O
A1	O
)	O
Agonist	O

7	O
.	O
69E	O
-	O
159	O

Thymidine	B-GP
kinase	I-GP

2	O
.	O
7	O
.	O
1	O
.	O
21	O

Thymidine	B-GP
Kinase	I-GP
Inhibitor	O

3	O
.	O
19E	O
-	O
151	O

Dihydrofolate	B-GP
reductase	I-GP

1	O
.	O
5	O
.	O
1	O
.	O
3	O

Glycinamide	B-GP
Ribonucleotide	I-GP
Formyltransferase	I-GP
Inhibitor	O

1	O
.	O
02E	O
-	O
134	O

Catechol	O
O	O
-	O
methyltransferase	O

2	O
.	O
1	O
.	O
1	O
.	O
6	O

S	B-GP
-	I-GP
Adenosyl	I-GP
-	I-GP
L	I-GP
-	I-GP
Homocysteine	I-GP
Hydrolase	I-GP
Inhibitor	O

4	O
.	O
67E	O
-	O
127	O

Prostaglandin	O
-	O
endoperoxide	O
synthase	O

1	O
.	O
14	O
.	O
99	O
.	O
1	O

Prostaglandin	O

8	O
.	O
57E	O
-	O
110	O

Purine	O
-	O
nucleoside	O
phosphorylase	O

2	O
.	O
4	O
.	O
2	O
.	O
1	O

Adenosine	O
(	O
A1	O
)	O
Agonist	O

8	O
.	O
35E	O
-	O
105	O

Ribose	O
-	O
phosphate	O
pyrophosphokinase	O

2	O
.	O
7	O
.	O
6	O
.	O
1	O

S	B-GP
-	I-GP
Adenosyl	I-GP
-	I-GP
L	I-GP
-	I-GP
Homocysteine	I-GP
Hydrolase	I-GP
Inhibitor	O

4	O
.	O
33E	O
-	O
91	O

Phosphoribosylglycinamide	B-GP
formyltransferase	I-GP

2	O
.	O
1	O
.	O
2	O
.	O
2	O

Glycinamide	B-GP
Ribonucleotide	I-GP
Formyltransferase	I-GP
Inhibitor	O

1	O
.	O
55E	O
-	O
82	O

Phosphoribosylaminoimidazolecarboxamide	O
formyltransferase	O

2	O
.	O
1	O
.	O
2	O
.	O
3	O

Glycinamide	B-GP
Ribonucleotide	I-GP
Formyltransferase	I-GP
Inhibitor	O

9	O
.	O
12E	O
-	O
80	O

3	O
′,	O
5	O
′-	O
cyclic	O
-	O
nucleotide	O
phosphodiesterase	O

3	O
.	O
1	O
.	O
4	O
.	O
17	O

S	B-GP
-	I-GP
Adenosyl	I-GP
-	I-GP
L	I-GP
-	I-GP
Homocysteine	I-GP
Hydrolase	I-GP
Inhibitor	O

1	O
.	O
23E	O
-	O
77	O

Thymidylate	B-GP
synthase	I-GP

2	O
.	O
1	O
.	O
1	O
.	O
45	O

Thymidylate	B-GP
Synthetase	I-GP
Inhibitor	O

2	O
.	O
54E	O
-	O
75	O

Steryl	O
-	O
sulfatase	O

3	O
.	O
1	O
.	O
6	O
.	O
2	O

Aromatase	B-GP
Inhibitor	O

4	O
.	O
90E	O
-	O
62	O

Guanylate	O
cyclase	O

4	O
.	O
6	O
.	O
1	O
.	O
2	O

Purine	O
Nucleoside	O
Phosphorylase	O
Inhibitor	O

2	O
.	O
68E	O
-	O
60	O

Cholestenone	O
5	O
-	O
alpha	O
-	O
reductase	O

1	O
.	O
3	O
.	O
1	O
.	O
22	O

Steroid	B-GP
(	I-GP
5alpha	I-GP
)	I-GP
Reductase	I-GP
Inhibitor	O

3	O
.	O
63E	O
-	O
60	O

Steroid	O
17	O
-	O
alpha	O
-	O
monooxygenase	O

1	O
.	O
14	O
.	O
99	O
.	O
9	O

Steroid	B-GP
(	I-GP
5alpha	I-GP
)	I-GP
Reductase	I-GP
Inhibitor	O

1	O
.	O
37E	O
-	O
58	O

RNA	O
-	O
directed	O
DNA	O
polymerase	O

2	O
.	O
7	O
.	O
7	O
.	O
49	O

S	B-GP
-	I-GP
Adenosyl	I-GP
-	I-GP
L	I-GP
-	I-GP
Homocysteine	I-GP
Hydrolase	I-GP
Inhibitor	O

1	O
.	O
06E	O
-	O
52	O

Alpha	O
-	O
glucosidase	O

3	O
.	O
2	O
.	O
1	O
.	O
20	O

Glucosidase	O
(	O
alpha	O
)	O
Inhibitor	O

1	O
.	O
00E	O
-	O
51	O

Farnesyl	O
-	O
diphosphate	O
farnesyltransferase	O

2	O
.	O
5	O
.	O
1	O
.	O
21	O

Squalene	B-GP
Synthase	I-GP
Inhibitor	O

2	O
.	O
12E	O
-	O
46	O

Beta	O
-	O
galactosidase	O

3	O
.	O
2	O
.	O
1	O
.	O
23	O

Glucosidase	O
(	O
alpha	O
)	O
Inhibitor	O

4	O
.	O
04E	O
-	O
46	O

Sterol	B-GP
esterase	I-GP

3	O
.	O
1	O
.	O
1	O
.	O
13	O

Phospholipase	B-GP
A2	I-GP
Inhibitor	O

3	O
.	O
18E	O
-	O
44	O

Leukotriene	O
-	O
A4	O
hydrolase	O

3	O
.	O
3	O
.	O
2	O
.	O
6	O

Prostaglandin	O

5	O
.	O
16E	O
-	O
40	O

Squalene	O
monooxygenase	O

1	O
.	O
14	O
.	O
99	O
.	O
7	O

Squalene	B-GP
Synthase	I-GP
Inhibitor	O

7	O
.	O
59E	O
-	O
40	O

Ribonucleoside	O
-	O
diphosphate	O
reductase	O

1	O
.	O
17	O
.	O
4	O
.	O
1	O

S	B-GP
-	I-GP
Adenosyl	I-GP
-	I-GP
L	I-GP
-	I-GP
Homocysteine	I-GP
Hydrolase	I-GP
Inhibitor	O

2	O
.	O
47E	O
-	O
38	O

3	O
-	O
hydroxyanthranilate	O
3	O
,	O
4	O
-	O
dioxygenase	O

1	O
.	O
13	O
.	O
11	O
.	O
6	O

3	O
-	O
Hydroxyanthranilate	O
Oxygenase	O
Inhibitor	O

1	O
.	O
14E	O
-	O
33	O

Dihydroorotase	B-GP

3	O
.	O
5	O
.	O
2	O
.	O
3	O

Dihydroorotase	B-GP
Inhibitor	O

2	O
.	O
25E	O
-	O
32	O

Nitric	O
-	O
oxide	O
synthase	O

1	O
.	O
14	O
.	O
13	O
.	O
39	O

Nitric	B-GP
Oxide	I-GP
Synthase	I-GP
Inhibitor	O

8	O
.	O
86E	O
-	O
28	O

Phospholipase	B-GP
A2	I-GP

3	O
.	O
1	O
.	O
1	O
.	O
4	O

Phospholipase	B-GP
A2	I-GP
Inhibitor	O

9	O
.	O
82E	O
-	O
26	O

Diaminopimelate	O
epimerase	O

5	O
.	O
1	O
.	O
1	O
.	O
7	O

Nitric	B-GP
Oxide	I-GP
Synthase	I-GP
Inhibitor	O

2	O
.	O
43E	O
-	O
24	O

Membrane	O
dipeptidase	O

3	O
.	O
4	O
.	O
13	O
.	O
19	O

Nitric	B-GP
Oxide	I-GP
Synthase	I-GP
Inhibitor	O

2	O
.	O
81E	O
-	O
23	O

3	O
-	O
alpha	O
(	O
or	O
20	O
-	O
beta	O
)-	O
hydroxysteroid	O
dehydrogenase	O

1	O
.	O
1	O
.	O
1	O
.	O
53	O

Aromatase	B-GP
Inhibitor	O

1	O
.	O
51E	O
-	O
22	O

Sterol	O
O	O
-	O
acyltransferase	O

2	O
.	O
3	O
.	O
1	O
.	O
26	O

Adenosine	O
(	O
A2	O
)	O
Agonist	O

4	O
.	O
95E	O
-	O
22	O

Hydroxymethylglutaryl	O
-	O
CoA	O
reductase	O
(	O
NADPH	O
)	O

1	O
.	O
1	O
.	O
1	O
.	O
34	O

Adenosine	O
(	O
A2	O
)	O
Agonist	O

4	O
.	O
95E	O
-	O
22	O

IMP	O
dehydrogenase	O

1	O
.	O
1	O
.	O
1	O
.	O
205	O

Adenosine	O
(	O
A1	O
)	O
Agonist	O

8	O
.	O
98E	O
-	O
17	O

ATP	O
-	O
citrate	O
(	O
pro	O
-	O
S	O
-)-	O
lyase	O

4	O
.	O
1	O
.	O
3	O
.	O
8	O

Adenosine	O
(	O
A2	O
)	O
Agonist	O

1	O
.	O
83E	O
-	O
15	O

Glutamate	O
–	O
cysteine	O
ligase	O

6	O
.	O
3	O
.	O
2	O
.	O
2	O

Nitric	B-GP
Oxide	I-GP
Synthase	I-GP
Inhibitor	O

2	O
.	O
71E	O
-	O
11	O

Dopamine	O
-	O
beta	O
-	O
monooxygenase	O

1	O
.	O
14	O
.	O
17	O
.	O
1	O

Adrenergic	O
(	O
beta1	O
)	O
Agonist	O

3	O
.	O
81E	O
-	O
11	O

Lanosterol	O
synthase	O

5	O
.	O
4	O
.	O
99	O
.	O
7	O

Squalene	B-GP
Synthase	I-GP
Inhibitor	O

1	O
.	O
38E	O
-	O
10	O

Nucleoside	O
-	O
diphosphate	O
kinase	B-GP

2	O
.	O
7	O
.	O
4	O
.	O
6	O

P2T	O
Purinoreceptor	O
Antagonist	O

2	O
.	O
76E	O
-	O
10	O

Exact	O
matches	O
(	O
the	O
enzyme	O
is	O
the	O
canonical	O
target	O
of	O
the	O
best	O
MDDR	O
hit	O
)	O
are	O
shown	O
in	O
bold	O
type	O
,	O
pathway	O
matches	O
(	O
the	O
enzyme	O
shares	O
the	O
same	O
pathway	O
as	O
the	O
canonical	O
target	O
of	O
the	O
best	O
MDDR	O
hit	O
)	O
are	O
shown	O
in	O
italic	O
type	O
,	O
and	O
enzymes	O
not	O
in	O
the	O
same	O
pathway	O
as	O
the	O
canonical	O
target	O
are	O
shown	O
in	O
regular	O
type	O
.	O

Other	O
links	O
recovered	O
off	O
-	O
pathway	O
hits	O
,	O
which	O
often	O
reflect	O
known	O
polypharmacology	O
that	O
is	O
well	O
-	O
documented	O
.	O

For	O
example	O
,	O
the	O
glycinamide	B-GP
ribonucleotide	I-GP
formyltransferase	I-GP
(	O
GART	B-GP
)	O
inhibitor	O
drug	O
set	O
hits	O
both	O
the	O
GART	B-GP
reaction	O
set	O
(	O
E	O
=	O
1	O
.	O
55	O
×	O
10	O
−	O
82	O
)	O
and	O
the	O
off	O
-	O
pathway	O
but	O
pharmacologically	O
related	O
antifolate	O
target	O
dihydrofolate	B-GP
reductase	I-GP
(	O
DHFR	B-GP
)	O
(	O
E	O
=	O
1	O
.	O
02	O
×	O
10	O
−	O
134	O
).	O

Other	O
off	O
-	O
pathway	O
hits	O
reflect	O
biological	O
connections	O
,	O
or	O
physical	O
connections	O
,	O
between	O
targets	O
.	O

For	O
example	O
,	O
the	O
adenosine	B-GP
deaminase	I-GP
reaction	O
set	O
links	O
to	O
the	O
A1	O
adenosine	O
receptor	O
agonist	O
drug	O
set	O
(	O
E	O
=	O
7	O
.	O
69	O
×	O
10	O
−	O
159	O
)	O
(	O
Table	O
1	O
)	O
capturing	O
the	O
known	O
interaction	O
between	O
A1	O
adenosine	O
receptors	O
and	O
adenosine	B-GP
deaminase	I-GP
on	O
the	O
cell	O
surface	O
of	O
smooth	O
muscle	O
cells	O
[	O
33	O
].	O

Considering	O
only	O
the	O
stringent	O
case	O
of	O
exact	O
matches	O
based	O
on	O
EC	O
numbers	O
,	O
a	O
Mann	O
-	O
Whitney	O
rank	O
-	O
sum	O
test	O
(	O
also	O
referred	O
to	O
as	O
the	O
U	O
-	O
test	O
)	O
shows	O
that	O
the	O
expectation	O
values	O
for	O
links	O
between	O
reaction	O
sets	O
and	O
drug	O
sets	O
of	O
known	O
drug	O
target	O
enzymes	O
were	O
significantly	O
better	O
than	O
the	O
expectation	O
values	O
for	O
links	O
to	O
reaction	O
sets	O
of	O
non	O
-	O
target	O
enzymes	O
,	O
i	O
.	O
e	O
.,	O
62	O
known	O
enzyme	O
targets	O
were	O
recovered	O
in	O
a	O
background	O
of	O
4	O
,	O
920	O
non	O
-	O
target	O
“	O
other	O
”	O
enzymes	O
at	O
a	O
statistical	O
significance	O
of	O
P	O
=	O
2	O
.	O
01	O
×	O
10	O
−	O
6	O
.	O

In	O
addition	O
to	O
recapitulating	O
many	O
known	O
drug	O
-	O
target	O
interactions	O
,	O
the	O
links	O
identified	O
by	O
these	O
comparisons	O
also	O
suggest	O
new	O
hypotheses	O
about	O
drug	O
-	O
target	O
interactions	O
.	O

One	O
such	O
new	O
prediction	O
involves	O
the	O
phospholipase	B-GP
A2	I-GP
(	O
PLA2	B-GP
)	O
inhibitor	O
drug	O
class	O
.	O

The	O
substrates	O
and	O
products	O
of	O
PLA2	B-GP
recapitulate	O
its	O
known	O
link	O
to	O
the	O
PLA2	B-GP
inhibitor	O
drug	O
set	O
(	O
E	O
=	O
9	O
.	O
82	O
×	O
10	O
−	O
26	O
),	O
however	O
,	O
the	O
sterol	B-GP
esterase	I-GP
reaction	O
returns	O
an	O
even	O
better	O
score	O
against	O
the	O
PLA2	B-GP
inhibitor	O
set	O
(	O
E	O
=	O
3	O
.	O
18	O
×	O
10	O
−	O
44	O
)	O
(	O
Table	O
1	O
).	O

Although	O
this	O
predicted	O
pharmacological	O
relationship	O
has	O
,	O
to	O
our	O
knowledge	O
,	O
not	O
been	O
previously	O
documented	O
,	O
the	O
result	O
is	O
consistent	O
with	O
the	O
known	O
biological	O
relationship	O
between	O
PLA2	B-GP
and	O
sterol	B-GP
esterase	I-GP
.	O

Both	O
enzymes	O
are	O
secreted	O
by	O
the	O
pancreas	O
and	O
require	O
phosphatidylcholine	O
hydrolysis	O
to	O
facilitate	O
intestinal	O
cholesterol	O
uptake	O
[	O
34	O
].	O

Thus	O
,	O
this	O
link	O
suggests	O
that	O
therapeutic	O
agents	O
directed	O
against	O
PLA2	B-GP
may	O
also	O
inhibit	O
sterol	B-GP
esterase	I-GP
,	O
perhaps	O
even	O
more	O
strongly	O
than	O
their	O
intended	O
target	O
.	O

Human	B-OG
drug	O
“	O
effect	O
-	O
space	O
”	O
maps	O
detail	O
interactions	O
between	O
drug	O
classes	O
and	O
enzyme	O
targets	O

To	O
present	O
links	O
between	O
small	O
molecule	O
metabolites	O
and	O
drugs	O
in	O
the	O
context	O
of	O
their	O
known	O
(	O
and	O
potential	O
)	O
metabolic	O
targets	O
,	O
metabolic	O
“	O
effect	O
-	O
space	O
”	O
maps	O
for	O
currently	O
marketed	O
drugs	O
were	O
generated	O
for	O
each	O
of	O
the	O
246	O
drug	O
classes	O
investigated	O
in	O
this	O
work	O
.	O

These	O
maps	O
enable	O
visualization	O
of	O
the	O
chemical	O
similarities	O
between	O
drugs	O
and	O
metabolites	O
painted	O
onto	O
human	B-OG
metabolic	O
pathways	O
,	O
illustrating	O
potential	O
interactions	O
between	O
an	O
individual	O
drug	O
class	O
and	O
specific	O
metabolic	O
enzymes	O
in	O
humans	B-OG
.	O

Examples	O
include	O
the	O
nucleoside	O
reverse	B-GP
transcriptase	I-GP
,	O
dihydrofolate	B-GP
reductase	I-GP
,	O
and	O
thymidylate	B-GP
synthase	I-GP
inhibitors	O
which	O
target	O
pyrimidine	O
nucleotide	O
metabolism	O
and	O
biosynthesis	O
of	O
the	O
essential	O
coenzyme	O
folate	O
(	O
Figure	O
3	O
and	O
Table	O
2	O
).	O

Using	O
the	O
canonical	O
human	B-OG
metabolic	O
pathways	O
from	O
HumanCyc	O
[	O
35	O
],	O
a	O
subset	O
of	O
the	O
BioCyc	O
[	O
12	O
]	O
database	O
collection	O
,	O
reactions	O
in	O
each	O
metabolic	O
network	O
have	O
been	O
colored	O
according	O
to	O
their	O
similarity	O
to	O
known	O
drug	O
classes	O
(	O
Figure	O
3	O
).	O

While	O
Table	O
1	O
presents	O
only	O
the	O
top	O
link	O
for	O
each	O
of	O
62	O
enzyme	O
targets	O
in	O
MetaCyc	O
against	O
the	O
246	O
MDDR	O
drug	O
classes	O
,	O
the	O
networks	O
in	O
Figure	O
3	O
detail	O
all	O
significant	O
hits	O
for	O
selected	O
drug	O
classes	O
against	O
the	O
pyrimidine	O
and	O
folate	O
pathways	O
.	O

Interactive	O
versions	O
of	O
these	O
maps	O
,	O
one	O
for	O
each	O
of	O
the	O
246	O
drug	O
classes	O
included	O
in	O
our	O
analysis	O
,	O
are	O
available	O
online	O
(	O
see	O
below	O
).	O

Effect	O
-	O
space	O
map	O
showing	O
chemical	O
similarity	O
between	O
specific	O
drug	O
classes	O
and	O
metabolites	O
in	O
human	B-OG
folate	O
and	O
pyrimidine	O
biosynthesis	O
.	O

Each	O
node	O
represents	O
one	O
reaction	O
set	O
–	O
the	O
substrates	O
and	O
products	O
of	O
a	O
single	O
human	B-OG
metabolic	O
reaction	O
.	O

Edges	O
connect	O
the	O
reactions	O
in	O
the	O
canonical	O
pathway	O
as	O
annotated	O
in	O
HumanCyc	O
[	O
35	O
].	O

As	O
given	O
in	O
the	O
color	O
key	O
,	O
each	O
reaction	O
is	O
colored	O
according	O
to	O
the	O
expectation	O
value	O
indicating	O
the	O
strength	O
of	O
similarity	O
between	O
that	O
target	O
reaction	O
set	O
and	O
the	O
respective	O
MDDR	O
drug	O
set	O
.	O

Diamond	O
shaped	O
nodes	O
indicate	O
reactions	O
catalyzed	O
by	O
enzymes	O
annotated	O
as	O
known	O
drug	O
targets	O
in	O
the	O
MDDR	O
;	O
circles	O
indicate	O
reactions	O
catalyzed	O
by	O
enzymes	O
not	O
annotated	O
as	O
targets	O
.	O

Reaction	O
key	O
:	O
1	O
.	O

Deoxyuridine	B-GP
kinase	I-GP
2	O
.	O

Thymidine	B-GP
kinase	I-GP
3	O
.	O

Thymidylate	B-GP
kinase	I-GP
4	O
.	O

Deoxythymidine	B-GP
diphosphate	I-GP
kinase	I-GP
5	O
.	O

Thymidylate	B-GP
synthase	I-GP
(	O
TS	B-GP
)	O
6	O
.	O

Methylene	B-GP
tetrahydrofolate	I-GP
reductase	I-GP
7	O
.	O

Dihydrofolate	B-GP
reductase	I-GP
(	O
DHFR	B-GP
)	O
8	O
.	O

Deoxyuridine	B-GP
diphosphate	I-GP
kinase	I-GP
9	O
.	O

Deoxyuridine	O
triphosphate	O
diphosphatase	O
.	O

Links	O
between	O
selected	O
drug	O
classes	O
and	O
top	O
ranked	O
metabolic	O
reactions	O
.	O

Rank	O

Thymidylate	B-GP
Synthetase	I-GP
(	O
TS	B-GP
)	O
Inhibitor	O

E	O
-	O
value	O

1	O

Dihydrofolate	B-GP
reductase	I-GP
(	O
DHFR	B-GP
)	O

1	O
.	O
96E	O
-	O
123	O

2	O

Methyltetrahydrofolate	O
-	O
corrinoid	O
-	O
iron	O
-	O
sulfur	O
protein	O
methyltransferase	O

3	O
.	O
58E	O
-	O
102	O

3	O

Methionyl	B-GP
-	I-GP
tRNA	I-GP
formyltransferase	I-GP

1	O
.	O
97E	O
-	O
99	O

4	O

Methylenetetrahydrofolate	O
reductase	O

2	O
.	O
67E	O
-	O
86	O

5	O

Thymidylate	B-GP
synthase	I-GP
(	O
TS	B-GP
)	O

2	O
.	O
54E	O
-	O
75	O

6	O

Formate	B-GP
-	I-GP
tetrahydrofolate	I-GP
ligase	I-GP

1	O
.	O
44E	O
-	O
74	O

7	O

Dihydrofolate	B-GP
synthetase	I-GP

1	O
.	O
35E	O
-	O
70	O

8	O

Aminomethyltransferase	B-GP

7	O
.	O
13E	O
-	O
63	O

9	O

5	O
-	O
methyltetrahydrofolate	O
-	O
homocysteine	O
S	O
-	O
methyltransferase	O

2	O
.	O
80E	O
-	O
62	O

10	O

Phosphoribosylaminoimidazolecarboxamide	O
(	O
AICAR	O
)	O
formyltransferase	O

1	O
.	O
50E	O
-	O
60	O

11	O

Phosphoribosylglycinamide	B-GP
formyltransferase	I-GP
(	O
GART	B-GP
)	O

1	O
.	O
50E	O
-	O
60	O

Rank	O

Dihydrofolate	B-GP
Reductase	I-GP
(	O
DHFR	B-GP
)	O
Inhibitor	O

E	O
-	O
value	O

1	O

Dihydrofolate	B-GP
reductase	I-GP
(	O
DHFR	B-GP
)	O

1	O
.	O
46E	O
-	O
82	O

2	O

Methyltetrahydrofolate	O
-	O
corrinoid	O
-	O
iron	O
-	O
sulfur	O
protein	O
methyltransferase	O

2	O
.	O
84E	O
-	O
75	O

3	O

Methylenetetrahydrofolate	O
reductase	O

6	O
.	O
01E	O
-	O
73	O

4	O

Methionyl	B-GP
-	I-GP
tRNA	I-GP
formyltransferase	I-GP

7	O
.	O
00E	O
-	O
66	O

5	O

Aminomethyltransferase	B-GP

6	O
.	O
90E	O
-	O
55	O

6	O

Formate	B-GP
-	I-GP
tetrahydrofolate	I-GP
ligase	I-GP

6	O
.	O
15E	O
-	O
49	O

7	O

Thymidylate	B-GP
synthase	I-GP
(	O
TS	B-GP
)	O

1	O
.	O
91E	O
-	O
48	O

8	O

5	O
-	O
methyltetrahydrofolate	O
-	O
homocysteine	O
S	O
-	O
methyltransferase	O

2	O
.	O
60E	O
-	O
45	O

9	O

3	O
-	O
methyl	O
-	O
2	O
-	O
oxobutanoate	O
hydroxymethyltransferase	O

2	O
.	O
68E	O
-	O
44	O

10	O

Glycine	O
decarboxylase	O

2	O
.	O
68E	O
-	O
44	O

11	O

Glycine	O
hydroxymethyltransferase	O
(	O
SHMT	B-GP
)	O

2	O
.	O
68E	O
-	O
44	O

12	O

Dihydrofolate	B-GP
synthetase	I-GP

9	O
.	O
65E	O
-	O
42	O

13	O

Phosphoribosylaminoimidazolecarboxamide	O
(	O
AICAR	O
)	O
formyltransferase	O

2	O
.	O
21E	O
-	O
39	O

14	O

Phosphoribosylglycinamide	B-GP
formyltransferase	I-GP
(	O
GART	B-GP
)	O

2	O
.	O
21E	O
-	O
39	O

Rank	O

Nucleoside	O
Reverse	B-GP
Transcriptase	I-GP
Inhibitor	O
(	O
NRTI	O
)	O

E	O
-	O
value	O

1	O

Thymidylate	B-GP
kinase	I-GP

7	O
.	O
48E	O
-	O
28	O

2	O

Thymidine	B-GP
kinase	I-GP

3	O
.	O
48E	O
-	O
26	O

3	O

Deoxythymidine	B-GP
diphosphate	I-GP
kinase	I-GP

1	O
.	O
54E	O
-	O
24	O

4	O

Ribonucleoside	O
-	O
triphosphate	O
reductase	O

2	O
.	O
88E	O
-	O
14	O

5	O

Deoxyuridine	O
triphosphate	O
pyrophosphatase	O

5	O
.	O
60E	O
-	O
12	O

6	O

Deoxyuridine	B-GP
kinase	I-GP

1	O
.	O
14E	O
-	O
11	O

7	O

Deoxyuridine	B-GP
diphosphate	I-GP
kinase	I-GP

1	O
.	O
45E	O
-	O
11	O

8	O

Thymidylate	B-GP
synthase	I-GP
(	O
TS	B-GP
)	O

5	O
.	O
68E	O
-	O
11	O

It	O
has	O
previously	O
been	O
shown	O
that	O
chemical	O
similarity	O
between	O
known	O
drugs	O
often	O
suggests	O
novel	O
drug	O
-	O
target	O
interactions	O
[	O
5	O
]–[	O
7	O
],[	O
14	O
].	O

Consistent	O
with	O
these	O
observations	O
,	O
effect	O
-	O
space	O
maps	O
such	O
as	O
those	O
shown	O
in	O
Figure	O
3	O
can	O
also	O
be	O
used	O
to	O
exploit	O
chemical	O
similarities	O
between	O
drugs	O
and	O
metabolites	O
to	O
indicate	O
potential	O
routes	O
of	O
drug	O
metabolism	O
and	O
toxicity	O
[	O
3	O
],[	O
11	O
],[	O
36	O
],[	O
37	O
].	O

For	O
example	O
,	O
the	O
nucleotide	O
reverse	B-GP
transcriptase	I-GP
inhibitors	O
(	O
NRTIs	O
)	O
used	O
in	O
HIV	B-OG
therapy	O
are	O
administered	O
as	O
pro	O
-	O
drugs	O
.	O

The	O
effect	O
-	O
space	O
map	O
reflects	O
this	O
route	O
of	O
NRTI	O
metabolism	O
leading	O
to	O
viral	O
inhibition	O
.	O

The	O
top	O
three	O
hits	O
yielded	O
by	O
the	O
NRTI	O
drug	O
set	O
queried	O
against	O
human	B-OG
metabolism	O
–	O
thymidine	B-GP
kinase	I-GP
(	O
E	O
=	O
3	O
.	O
48	O
×	O
10	O
−	O
26	O
),	O
thymidylate	B-GP
kinase	I-GP
(	O
E	O
=	O
7	O
.	O
48	O
×	O
10	O
−	O
28	O
),	O
and	O
deoxythymidine	B-GP
diphosphate	I-GP
kinase	I-GP
(	O
E	O
=	O
1	O
.	O
54	O
×	O
10	O
−	O
24	O
)	O
(	O
Figure	O
3	O
reaction	O
numbers	O
2	O
,	O
3	O
,	O
and	O
4	O
;	O
additional	O
results	O
in	O
Table	O
2	O
)	O
–	O
successively	O
phosphorylate	O
the	O
NRTI	O
pro	O
-	O
drugs	O
into	O
the	O
pharmacologically	O
active	O
NRTI	O
triphosphates	O
[	O
38	O
],[	O
39	O
].	O

The	O
viral	O
reverse	B-GP
transcriptase	I-GP
enzyme	O
then	O
incorporates	O
the	O
fully	O
phosphorylated	O
NRTIs	O
into	O
the	O
growing	O
DNA	O
strand	O
,	O
thereby	O
terminating	O
transcription	O
of	O
the	O
viral	O
DNA	O
.	O

In	O
this	O
example	O
,	O
considerable	O
toxicity	O
mitigates	O
the	O
therapeutic	O
value	O
of	O
inhibiting	O
viral	O
DNA	O
transcription	O
since	O
the	O
phosphorylated	O
NRTIs	O
directly	O
inhibit	O
human	B-OG
nucleotide	B-GP
kinases	I-GP
and	O
mitochondrial	B-GP
DNA	I-GP
pol	I-GP
-	I-GP
γ	I-GP
.	O

They	O
also	O
may	O
be	O
incorporated	O
by	O
pol	B-GP
-	I-GP
γ	I-GP
into	O
the	O
growing	O
human	B-OG
mitochondrial	O
DNA	O
strand	O
,	O
and	O
once	O
incorporated	O
are	O
inefficiently	O
excised	O
by	O
DNA	O
pol	O
-	O
γ	O
exonuclease	B-GP
[	O
40	O
].	O

Thus	O
,	O
the	O
effect	O
-	O
space	O
map	O
illustrates	O
both	O
the	O
route	O
of	O
metabolism	O
and	O
a	O
mechanism	O
of	O
toxicity	O
for	O
NRTIs	O
in	O
humans	B-OG
.	O

Drug	O
effect	O
-	O
space	O
maps	O
also	O
offer	O
a	O
broad	O
glimpse	O
of	O
potential	O
human	B-OG
metabolic	O
interactions	O
predicting	O
new	O
“	O
polypharmacology	O
”.	O

From	O
the	O
ligand	O
perspective	O
,	O
“	O
drug	O
polypharmacology	O
”	O
refers	O
to	O
a	O
single	O
drug	O
or	O
drug	O
class	O
that	O
hits	O
multiple	O
targets	O
.	O

For	O
example	O
,	O
dihydrofolate	B-GP
reductase	I-GP
(	O
DHFR	B-GP
,	O
reaction	O
number	O
7	O
in	O
Figure	O
3	O
)	O
uses	O
NADPH	O
to	O
reduce	O
7	O
,	O
8	O
-	O
dihydrofolate	O
to	O
tetrahydrofolate	O
.	O

Antifolate	O
drugs	O
inhibit	O
DHFR	B-GP
,	O
and	O
,	O
as	O
expected	O
,	O
the	O
DHFR	B-GP
drug	O
set	O
recovers	O
the	O
DHFR	B-GP
reaction	O
substrates	O
and	O
products	O
as	O
the	O
top	O
similarity	O
hit	O
in	O
human	B-OG
metabolism	O
(	O
E	O
=	O
1	O
.	O
46	O
×	O
10	O
−	O
82	O
)	O
(	O
Figure	O
3	O
,	O
Table	O
2	O
,	O
Figure	O
4	O
).	O

However	O
,	O
at	O
least	O
20	O
other	O
reactions	O
also	O
use	O
folate	O
coenzymes	O
in	O
human	B-OG
metabolism	O
[	O
41	O
]–[	O
43	O
].	O

Accordingly	O
,	O
SEA	O
finds	O
additional	O
links	O
between	O
the	O
DHFR	B-GP
drug	O
set	O
and	O
established	O
antifolate	O
targets	O
outside	O
the	O
pyrimidine	O
and	O
folate	O
biosynthesis	O
pathways	O
such	O
as	O
serine	O
hydroxymethyltransferase	O
(	O
SHMT	B-GP
,	O
E	O
=	O
2	O
.	O
68	O
×	O
10	O
−	O
44	O
),	O
phosphoribosyl	O
-	O
aminoimidazole	O
-	O
carboxamide	O
formyltransferase	O
(	O
AICAR	O
transformylase	O
,	O
E	O
=	O
2	O
.	O
21	O
×	O
10	O
−	O
39	O
),	O
and	O
phosphoribosyl	O
-	O
glycinamide	O
formyltransferase	O
(	O
GART	B-GP
,	O
E	O
=	O
2	O
.	O
21	O
×	O
10	O
−	O
39	O
)	O
(	O
Table	O
2	O
).	O

The	O
effect	O
-	O
space	O
maps	O
in	O
Figure	O
3	O
illustrate	O
the	O
results	O
from	O
Table	O
2	O
and	O
Figure	O
4	O
in	O
a	O
single	O
view	O
,	O
illustrating	O
drug	O
polypharmacology	O
with	O
respect	O
to	O
critical	O
metabolic	O
pathways	O
.	O

Selected	O
links	O
between	O
MDDR	O
drug	O
classes	O
and	O
human	B-OG
folate	O
and	O
pyrimidine	O
metabolism	O
.	O

Alternatively	O
,	O
from	O
the	O
target	O
perspective	O
,	O
“	O
target	O
polypharmacology	O
”	O
may	O
refer	O
to	O
a	O
single	O
target	O
being	O
modulated	O
by	O
multiple	O
classes	O
of	O
drugs	O
.	O

For	O
instance	O
,	O
thymidylate	B-GP
synthase	I-GP
(	O
TS	B-GP
)	O
is	O
another	O
classic	O
antifolate	O
target	O
that	O
uses	O
a	O
folate	O
coenzyme	O
to	O
methylate	O
deoxyuridine	O
phosphate	O
,	O
generating	O
deoxythymidine	O
phosphate	O
[	O
44	O
]–[	O
47	O
].	O

As	O
expected	O
,	O
the	O
TS	B-GP
reaction	O
links	O
to	O
known	O
antifolate	O
drug	O
classes	O
such	O
as	O
GART	B-GP
inhibitors	O
(	O
E	O
=	O
4	O
.	O
76	O
×	O
10	O
−	O
73	O
)	O
and	O
DHFR	B-GP
inhibitors	O
(	O
E	O
=	O
1	O
.	O
91	O
×	O
10	O
−	O
48	O
)	O
(	O
Table	O
3	O
and	O
Figure	O
4	O
).	O

However	O
,	O
TS	B-GP
is	O
also	O
effectively	O
inhibited	O
by	O
uracil	O
analogs	O
such	O
as	O
fluoropropynyl	O
deoxyuridine	O
,	O
which	O
is	O
not	O
a	O
folate	O
,	O
but	O
rather	O
a	O
pyrimidine	O
analog	O
.	O

Accordingly	O
,	O
the	O
TS	B-GP
reaction	O
also	O
links	O
to	O
reverse	B-GP
transcriptase	I-GP
inhibitors	O
,	O
which	O
include	O
fluoropropynyl	O
deoxyuridine	O
and	O
additional	O
pyrimidine	O
analogs	O
such	O
as	O
azidothymidine	O
(	O
AZT	O
)	O
(	O
E	O
=	O
5	O
.	O
68	O
×	O
10	O
−	O
11	O
)	O
(	O
Figure	O
4	O
).	O

The	O
target	O
polypharmacology	O
of	O
the	O
thymidylate	B-GP
synthase	I-GP
enzyme	O
is	O
mirrored	O
by	O
the	O
drug	O
polypharmacology	O
of	O
the	O
thymidylate	B-GP
synthase	I-GP
inhibitors	O
.	O

The	O
TS	B-GP
inhibitors	O
link	O
not	O
only	O
to	O
the	O
reactions	O
of	O
deoxyribonucleotide	O
biosynthesis	O
including	O
thymidylate	B-GP
synthase	I-GP
(	O
E	O
=	O
2	O
.	O
54	O
×	O
10	O
−	O
75	O
),	O
but	O
also	O
the	O
GART	B-GP
(	O
E	O
=	O
1	O
.	O
50	O
×	O
10	O
−	O
60	O
)	O
and	O
DHFR	B-GP
(	O
E	O
=	O
1	O
.	O
96	O
×	O
10	O
−	O
123	O
)	O
reactions	O
(	O
Figure	O
3	O
and	O
Table	O
2	O
).	O

Thus	O
,	O
SEA	O
recapitulates	O
the	O
known	O
polypharmacology	O
of	O
TS	B-GP
.	O

Effect	O
-	O
space	O
maps	O
illustrate	O
and	O
clarify	O
these	O
pharmacological	O
relationships	O
.	O

Links	O
between	O
selected	O
metabolic	O
reactions	O
and	O
top	O
ranked	O
drug	O
classes	O
.	O

Rank	O

Thymidylate	B-GP
Synthetase	I-GP
(	O
TS	B-GP
)	O
Reaction	O

E	O
-	O
value	O

1	O

Thymidylate	B-GP
synthase	I-GP
inhibitor	O
(	O
TS	B-GP
)	O

2	O
.	O
54E	O
-	O
75	O

2	O

Glycinamide	B-GP
ribonucleotide	I-GP
formyltransferase	I-GP
inhibitor	O
(	O
GART	B-GP
)	O

4	O
.	O
76E	O
-	O
73	O

3	O

Thymidine	B-GP
kinase	I-GP
inhibitor	O
(	O
TK	O
)	O

1	O
.	O
18E	O
-	O
62	O

4	O

Dihydrofolate	B-GP
reductase	I-GP
inhibitor	O
(	O
DHFR	B-GP
)	O

1	O
.	O
91E	O
-	O
48	O

5	O

Folylpolyglutamate	B-GP
synthetase	I-GP
inhibitor	O

2	O
.	O
27E	O
-	O
31	O

6	O

Nucleoside	O
reverse	B-GP
transcriptase	I-GP
inhibitor	O
(	O
NRTI	O
)	O

5	O
.	O
68E	O
-	O
11	O

Rank	O

Dihydrofolate	B-GP
Reductase	I-GP
(	O
DHFR	B-GP
)	O
Reaction	O

E	O
-	O
value	O

1	O

Glycinamide	B-GP
Ribonucleotide	I-GP
Formyltransferase	I-GP
Inhibitor	O

1	O
.	O
02E	O
-	O
134	O

2	O

Thymidylate	B-GP
Synthetase	I-GP
Inhibitor	O

1	O
.	O
96E	O
-	O
123	O

3	O

Dihydrofolate	B-GP
Reductase	I-GP
Inhibitor	O

1	O
.	O
46E	O
-	O
82	O

4	O

Folylpolyglutamate	B-GP
Synthetase	I-GP
Inhibitor	O

3	O
.	O
15E	O
-	O
62	O

Species	O
-	O
specific	O
effect	O
-	O
space	O
maps	O
for	O
pathogens	O
and	O
model	O
organisms	O

The	O
great	O
diversity	O
of	O
metabolic	O
strategies	O
,	O
pathways	O
,	O
and	O
enzymes	O
present	O
in	O
humans	B-OG
,	O
model	O
organisms	O
,	O
and	O
pathogenic	O
species	O
presents	O
both	O
opportunities	O
and	O
significant	O
barriers	O
to	O
drug	O
discovery	O
.	O

To	O
address	O
these	O
issues	O
,	O
species	O
-	O
specific	O
effect	O
-	O
space	O
maps	O
were	O
created	O
for	O
each	O
of	O
385	O
organisms	O
from	O
the	O
BioCyc	O
Database	O
Collection	O
.	O

Target	O
reactions	O
existing	O
in	O
common	O
and	O
differentially	O
between	O
each	O
of	O
these	O
species	O
and	O
humans	B-OG
are	O
shown	O
in	O
these	O
metabolic	O
maps	O
.	O

As	O
with	O
the	O
human	B-OG
effect	O
-	O
space	O
maps	O
,	O
this	O
set	O
of	O
maps	O
is	O
available	O
in	O
interactive	O
form	O
online	O
.	O

To	O
show	O
how	O
these	O
maps	O
may	O
be	O
used	O
to	O
provide	O
a	O
context	O
for	O
drug	O
discovery	O
,	O
MRSA	B-OG
is	O
used	O
as	O
an	O
example	O
(	O
Figure	O
5	O
).	O

The	O
global	O
view	O
of	O
drugs	O
and	O
metabolism	O
provided	O
by	O
this	O
species	O
-	O
specific	O
map	O
illustrates	O
some	O
of	O
the	O
daunting	O
challenges	O
to	O
the	O
selection	O
of	O
tractable	O
metabolic	O
drug	O
targets	O
in	O
this	O
organism	O
.	O

Effect	O
-	O
space	O
map	O
showing	O
chemical	O
similarity	O
between	O
drugs	O
and	O
metabolites	O
in	O
MRSA	B-OG
.	O

Canonical	O
pathway	O
representation	O
of	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
(	O
MRSA	B-OG
)	O
[	O
12	O
]	O
small	O
molecule	O
metabolism	O
colored	O
by	O
expectation	O
value	O
of	O
the	O
best	O
hit	O
against	O
MDDR	O
.	O

Reactions	O
that	O
are	O
also	O
present	O
in	O
humans	B-OG
have	O
been	O
faded	O
.	O

Layout	O
based	O
upon	O
the	O
Cytoscape	O
2	O
.	O
5	O
y	O
-	O
files	O
hierarchical	O
layout	O
.	O

Edge	O
lengths	O
are	O
not	O
significant	O
.	O

For	O
ease	O
of	O
viewing	O
,	O
reactions	O
are	O
not	O
labeled	O
but	O
can	O
be	O
identified	O
in	O
the	O
interactive	O
versions	O
of	O
the	O
maps	O
available	O
at	O
the	O
online	O
resource	O
.	O

As	O
described	O
for	O
Figure	O
3	O
,	O
each	O
node	O
in	O
the	O
MRSA	B-OG
network	O
in	O
Figure	O
5	O
represents	O
one	O
reaction	O
set	O
,	O
the	O
substrates	O
and	O
products	O
of	O
a	O
single	O
metabolic	O
reaction	O
.	O

Edges	O
connect	O
the	O
reactions	O
according	O
to	O
canonical	O
BioCyc	O
MRSA	B-OG
pathways	O
.	O

Each	O
reaction	O
in	O
the	O
network	O
has	O
been	O
colored	O
according	O
the	O
expectation	O
value	O
of	O
the	O
best	O
link	O
between	O
the	O
reaction	O
set	O
and	O
any	O
of	O
the	O
246	O
MDDR	O
drug	O
sets	O
.	O

Lighter	O
colored	O
nodes	O
have	O
higher	O
expectation	O
values	O
indicating	O
less	O
drug	O
-	O
like	O
reaction	O
sets	O
,	O
while	O
darker	O
colored	O
nodes	O
indicate	O
more	O
drug	O
-	O
like	O
reaction	O
sets	O
.	O

To	O
provide	O
therapeutic	O
context	O
,	O
reactions	O
that	O
are	O
also	O
present	O
in	O
human	B-OG
metabolism	O
have	O
been	O
faded	O
,	O
indicating	O
that	O
drug	O
sets	O
targeting	O
these	O
enzymes	O
in	O
MRSA	B-OG
may	O
have	O
the	O
undesirable	O
potential	O
to	O
inhibit	O
the	O
human	B-OG
enzymes	O
as	O
well	O
.	O

As	O
with	O
the	O
other	O
organisms	O
represented	O
in	O
our	O
online	O
maps	O
,	O
most	O
reactions	O
in	O
the	O
MRSA	B-OG
subset	O
have	O
little	O
chemical	O
similarity	O
to	O
any	O
MDDR	O
drug	O
set	O
.	O

Although	O
74	O
%	O
of	O
the	O
469	O
MRSA	B-OG
metabolic	O
reactions	O
have	O
measurable	O
similarity	O
to	O
at	O
least	O
one	O
MDDR	O
drug	O
set	O
,	O
only	O
36	O
%	O
of	O
these	O
links	O
had	O
expectation	O
values	O
of	O
E	O
=	O
1	O
.	O
0	O
×	O
10	O
−	O
10	O
or	O
better	O
.	O

Several	O
complete	O
pathways	O
of	O
diverse	O
chemical	O
classes	O
,	O
including	O
shikimic	O
acid	O
,	O
phospholipid	O
,	O
peptidoglycan	O
,	O
teichoic	O
acid	O
,	O
and	O
molybdenum	O
cofactor	O
biosynthesis	O
,	O
lack	O
links	O
to	O
any	O
drug	O
set	O
at	O
all	O
.	O

Only	O
18	O
of	O
the	O
469	O
MRSA	B-OG
metabolic	O
reactions	O
are	O
already	O
known	O
to	O
be	O
drug	O
targets	O
in	O
MDDR	O
.	O

Fourteen	O
of	O
these	O
are	O
represented	O
in	O
Figure	O
5	O
(	O
as	O
diamonds	O
),	O
but	O
all	O
18	O
of	O
these	O
also	O
appear	O
in	O
humans	B-OG
.	O

Enzymes	O
that	O
catalyze	O
these	O
reactions	O
in	O
humans	B-OG
would	O
likely	O
be	O
vulnerable	O
to	O
inhibitors	O
developed	O
against	O
these	O
MRSA	B-OG
targets	O
,	O
putting	O
those	O
drugs	O
at	O
risk	O
for	O
toxicity	O
.	O

Figure	O
6	O
illustrates	O
how	O
additional	O
information	O
can	O
be	O
used	O
to	O
further	O
filter	O
potential	O
metabolic	O
targets	O
by	O
painting	O
additional	O
biological	O
or	O
genomic	O
data	O
onto	O
a	O
species	O
-	O
specific	O
map	O
.	O

Since	O
successful	O
modulation	O
of	O
a	O
target	O
may	O
not	O
alone	O
be	O
sufficient	O
to	O
kill	O
a	O
pathogen	O
due	O
to	O
the	O
presence	O
of	O
redundant	O
pathways	O
for	O
the	O
formation	O
of	O
critical	O
metabolites	O
,	O
integration	O
of	O
such	O
additional	O
information	O
into	O
a	O
metabolic	O
map	O
may	O
provide	O
added	O
value	O
in	O
addressing	O
the	O
multi	O
-	O
dimensional	O
challenges	O
of	O
drug	O
discovery	O
.	O

Flux	O
balance	O
analysis	O
of	O
metabolic	O
networks	O
was	O
used	O
by	O
several	O
of	O
the	O
authors	O
of	O
this	O
work	O
to	O
identify	O
essential	O
enzymes	O
and	O
metabolites	O
required	O
for	O
the	O
formation	O
of	O
all	O
necessary	O
biomass	O
components	O
for	O
13	O
strains	O
of	O
Staphylococcus	O
aureus	O
including	O
the	O
methicillin	O
-	O
resistant	O
N315	O
strain	O
(	O
MRSA	B-OG
)	O
[	O
48	O
].	O

Using	O
these	O
results	O
,	O
39	O
essential	O
reactions	O
and	O
19	O
synthetic	O
lethal	O
reaction	O
pairs	O
could	O
be	O
mapped	O
to	O
our	O
dataset	O
(	O
Figure	O
6	O
),	O
highlighting	O
those	O
reactions	O
for	O
which	O
inhibition	O
is	O
most	O
likely	O
to	O
result	O
in	O
the	O
death	O
of	O
the	O
organism	O
.	O

Several	O
of	O
these	O
reactions	O
have	O
been	O
successfully	O
targeted	O
by	O
currently	O
marketed	O
drugs	O
,	O
such	O
as	O
the	O
previously	O
discussed	O
antifolate	O
targets	O
DHFR	B-GP
(	O
E	O
=	O
1	O
.	O
02	O
×	O
10	O
−	O
134	O
),	O
thymidylate	B-GP
synthase	I-GP
(	O
E	O
=	O
2	O
.	O
54	O
×	O
10	O
−	O
75	O
),	O
and	O
dihydrofolate	O
synthase	O
(	O
E	O
=	O
1	O
.	O
35	O
×	O
10	O
−	O
70	O
).	O

This	O
retrospective	O
result	O
illustrates	O
the	O
potential	O
of	O
such	O
additional	O
information	O
in	O
enriching	O
for	O
targets	O
and	O
drug	O
chemistry	O
that	O
have	O
been	O
proven	O
accessible	O
.	O

Other	O
targets	O
and	O
pathways	O
have	O
not	O
yet	O
yielded	O
successful	O
drugs	O
but	O
are	O
under	O
investigation	O
in	O
MRSA	B-OG
or	O
other	O
pathogens	O
,	O
such	O
as	O
the	O
shikimate	O
pathway	O
[	O
49	O
]	O
in	O
aromatic	O
amino	O
acid	O
biosynthesis	O
and	O
the	O
histidine	O
biosynthesis	O
pathway	O
[	O
50	O
].	O

Essential	O
and	O
synthetic	O
lethal	O
map	O
of	O
MRSA	B-OG
metabolism	O
.	O

Canonical	O
pathway	O
representation	O
of	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
(	O
MRSA	B-OG
)	O
small	O
molecule	O
metabolism	O
colored	O
by	O
essentiality	O
and	O
synthetic	O
lethality	O
of	O
reactions	O
.	O

Key	O
:	O
black	O
=	O
essential	O
reaction	O
;	O
other	O
colors	O
=	O
synthetic	O
lethal	O
reaction	O
pairs	O
;	O
node	O
size	O
=	O
similarity	O
to	O
top	O
MDDR	O
hit	O
(	O
bigger	O
is	O
more	O
drug	O
-	O
like	O
);	O
diamond	O
shape	O
=	O
MDDR	O
drug	O
target	O
;	O
faded	O
border	O
=	O
human	B-OG
reaction	O
.	O

The	O
combination	O
of	O
the	O
essentiality	O
data	O
with	O
the	O
drug	O
space	O
mapping	O
emphasizes	O
the	O
challenges	O
to	O
drug	O
discovery	O
against	O
MRSA	B-OG
.	O

Thus	O
,	O
while	O
species	O
-	O
specific	O
antifolates	O
do	O
exist	O
,	O
many	O
antifolates	O
such	O
as	O
methotrexate	O
used	O
in	O
cancer	B-DS
therapy	O
cause	O
severe	O
toxicity	O
[	O
43	O
].	O

To	O
avoid	O
such	O
toxicity	O
,	O
14	O
of	O
the	O
39	O
essential	O
MRSA	B-OG
reactions	O
that	O
are	O
also	O
present	O
in	O
humans	B-OG
can	O
be	O
excluded	O
from	O
further	O
consideration	O
as	O
drug	O
targets	O
in	O
MRSA	B-OG
.	O

A	O
compilation	O
of	O
all	O
of	O
the	O
metabolic	O
network	O
maps	O
generated	O
in	O
this	O
study	O
is	O
available	O
at	O
http	O
://	O
sea	O
.	O
docking	O
.	O
org	O
/	O
metabolism	O
.	O

These	O
include	O
interactive	O
versions	O
of	O
the	O
human	B-OG
effect	O
-	O
space	O
maps	O
shown	O
in	O
Figure	O
3	O
,	O
one	O
for	O
each	O
of	O
the	O
246	O
MDDR	O
drug	O
classes	O
analyzed	O
in	O
this	O
work	O
,	O
and	O
385	O
species	O
-	O
specific	O
maps	O
such	O
as	O
that	O
shown	O
in	O
Figure	O
5	O
.	O

The	O
species	O
-	O
specific	O
maps	O
were	O
generated	O
from	O
the	O
BioCyc	O
database	O
public	O
collection	O
,	O
a	O
compendium	O
of	O
385	O
model	O
organisms	O
and	O
pathogens	O
whose	O
genomes	O
have	O
been	O
sequenced	O
and	O
their	O
metabolomes	O
deciphered	O
.	O

Of	O
these	O
,	O
65	O
have	O
been	O
designated	O
as	O
Priority	O
Pathogens	O
by	O
the	O
National	O
Institute	O
of	O
Allergy	O
and	O
Infectious	O
Diseases	O
(	O
NIAID	O
)	O
and	O
include	O
Bacillus	B-OG
anthracis	I-OG
,	O
Brucella	O
melitensis	O
,	O
Cryptosporidium	O
parvum	O
,	O
Salmonella	O
,	O
SARS	B-OG
,	O
Toxoplasma	O
gondii	O
,	O
Vibrio	B-OG
cholerae	I-OG
,	O
and	O
Yersinia	B-OG
pestis	I-OG
[	O
51	O
].	O

Browse	O
and	O
similarity	O
search	O
tools	O
are	O
also	O
provided	O
,	O
allowing	O
exploration	O
of	O
the	O
metabolic	O
reaction	O
sets	O
and	O
current	O
drug	O
classes	O
used	O
in	O
this	O
work	O
,	O
as	O
well	O
as	O
comparison	O
to	O
user	O
-	O
defined	O
custom	O
ligand	O
sets	O
.	O

These	O
interactive	O
tools	O
enable	O
facile	O
exploration	O
between	O
the	O
vast	O
biological	O
data	O
on	O
potential	O
metabolic	O
drug	O
targets	O
in	O
these	O
organisms	O
and	O
the	O
drug	O
chemistry	O
currently	O
available	O
to	O
prosecute	O
those	O
targets	O
.	O

Discussion	O

A	O
key	O
product	O
of	O
this	O
study	O
is	O
the	O
construction	O
of	O
drug	O
-	O
metabolite	O
correspondence	O
maps	O
that	O
provide	O
both	O
a	O
global	O
view	O
and	O
a	O
more	O
contextual	O
picture	O
of	O
predicted	O
drug	O
action	O
in	O
human	B-OG
metabolism	O
than	O
has	O
been	O
previously	O
available	O
.	O

Several	O
aspects	O
of	O
these	O
maps	O
deserve	O
particular	O
emphasis	O
.	O

First	O
,	O
despite	O
the	O
differences	O
in	O
physiochemical	O
properties	O
of	O
most	O
drugs	O
and	O
small	O
molecule	O
metabolites	O
,	O
numerous	O
links	O
arise	O
between	O
drugs	O
and	O
metabolism	O
.	O

Viewed	O
in	O
the	O
context	O
of	O
metabolic	O
networks	O
,	O
the	O
pharmacological	O
relationships	O
predicted	O
by	O
these	O
links	O
can	O
be	O
readily	O
interpreted	O
in	O
a	O
way	O
that	O
is	O
biologically	O
sensible	O
.	O

Moreover	O
,	O
as	O
shown	O
by	O
both	O
the	O
drug	O
effect	O
space	O
maps	O
and	O
species	O
-	O
specific	O
maps	O
,	O
our	O
retrospective	O
analyses	O
confirm	O
that	O
biologically	O
and	O
pharmacologically	O
significant	O
connections	O
can	O
be	O
recovered	O
,	O
capturing	O
known	O
polypharmacology	O
and	O
revealing	O
the	O
relevant	O
chemotypes	O
previously	O
explored	O
in	O
drug	O
development	O
.	O

The	O
metabolome	O
-	O
wide	O
exploratory	O
tools	O
provided	O
with	O
these	O
map	O
sets	O
also	O
enable	O
a	O
new	O
way	O
to	O
interrogate	O
the	O
links	O
between	O
drugs	O
and	O
metabolism	O
that	O
will	O
likely	O
be	O
useful	O
for	O
prediction	O
of	O
new	O
targets	O
and	O
to	O
indicate	O
routes	O
of	O
drug	O
metabolism	O
and	O
toxicity	O
.	O

Further	O
,	O
by	O
integrating	O
biological	O
information	O
such	O
as	O
essentiality	O
and	O
synthetic	O
lethal	O
analyses	O
with	O
the	O
metabolic	O
context	O
,	O
our	O
approach	O
allows	O
users	O
to	O
focus	O
evaluation	O
of	O
potential	O
targets	O
around	O
specific	O
types	O
of	O
data	O
simply	O
by	O
painting	O
the	O
results	O
on	O
to	O
metabolic	O
maps	O
.	O

With	O
respect	O
to	O
the	O
coverage	O
of	O
drug	O
links	O
across	O
small	O
molecule	O
metabolism	O
that	O
this	O
study	O
provides	O
,	O
we	O
note	O
that	O
the	O
SEA	O
method	O
relies	O
solely	O
upon	O
the	O
chemical	O
similarity	O
of	O
ligands	O
to	O
establish	O
links	O
between	O
drug	O
sets	O
and	O
reaction	O
sets	O
.	O

Based	O
on	O
these	O
links	O
,	O
and	O
the	O
biologically	O
sensible	O
connections	O
shown	O
in	O
the	O
results	O
,	O
we	O
infer	O
that	O
a	O
particular	O
drug	O
class	O
may	O
act	O
on	O
a	O
certain	O
target	O
.	O

However	O
,	O
drugs	O
may	O
also	O
act	O
against	O
an	O
enzyme	O
active	O
site	O
without	O
resembling	O
the	O
endogenous	O
substrate	O
,	O
or	O
by	O
allosteric	O
regulation	O
at	O
an	O
entirely	O
different	O
site	O
.	O

The	O
SEA	O
method	O
,	O
as	O
applied	O
here	O
to	O
the	O
substrates	O
and	O
products	O
of	O
metabolic	O
reactions	O
,	O
does	O
not	O
capture	O
these	O
additional	O
drug	O
-	O
target	O
links	O
.	O

Other	O
viable	O
strategies	O
are	O
available	O
for	O
targeting	O
metabolic	O
enzyme	O
active	O
sites	O
that	O
use	O
principles	O
unrelated	O
to	O
the	O
ligand	O
-	O
drug	O
similarities	O
that	O
are	O
the	O
focus	O
of	O
our	O
approach	O
[	O
52	O
]–[	O
55	O
].	O

For	O
instance	O
,	O
Tondi	O
et	O
al	O
.	O
designed	O
novel	O
inhibitors	O
of	O
thymidylate	B-GP
synthase	I-GP
that	O
complemented	O
the	O
three	O
dimensional	O
structure	O
of	O
the	O
active	O
site	O
.	O

Five	O
high	O
-	O
scoring	O
compounds	O
selected	O
for	O
testing	O
were	O
dissimilar	O
to	O
the	O
substrate	O
but	O
bound	O
competitively	O
with	O
it	O
[	O
55	O
].	O

While	O
many	O
classical	O
kinase	B-GP
inhibitors	O
interact	O
directly	O
with	O
the	O
ATP	O
binding	O
site	O
,	O
imatinib	O
(	O
tradename	O
Gleevec	O
)	O
represents	O
a	O
new	O
generation	O
of	O
allosteric	O
protein	B-GP
kinase	I-GP
inhibitors	O
that	O
alter	O
the	O
kinase	B-GP
conformation	O
to	O
prevent	O
ATP	O
binding	O
.	O

Other	O
allosteric	O
kinase	B-GP
inhibitors	O
prevent	O
the	O
protein	O
substrate	O
from	O
loading	O
[	O
52	O
].	O

While	O
a	O
quantitative	O
determination	O
of	O
the	O
proportion	O
of	O
drug	O
-	O
target	O
links	O
that	O
cannot	O
be	O
accessed	O
by	O
our	O
approach	O
is	O
beyond	O
the	O
scope	O
of	O
this	O
study	O
,	O
we	O
can	O
provide	O
a	O
rough	O
estimate	O
for	O
the	O
frequency	O
of	O
such	O
cases	O
based	O
on	O
the	O
results	O
reported	O
in	O
Table	O
1	O
.	O

Of	O
the	O
62	O
known	O
enzyme	O
targets	O
in	O
MetaCyc	O
,	O
42	O
(	O
68	O
%)	O
the	O
substrate	O
/	O
product	O
metabolite	O
sets	O
show	O
significant	O
chemical	O
similarity	O
to	O
at	O
least	O
one	O
MDDR	O
drug	O
set	O
,	O
establishing	O
a	O
reasonable	O
first	O
pass	O
estimate	O
for	O
the	O
percentage	O
of	O
current	O
enzyme	O
targets	O
accessible	O
to	O
this	O
approach	O
.	O

Furthermore	O
,	O
40	O
%	O
(	O
2	O
,	O
044	O
of	O
5	O
,	O
056	O
)	O
of	O
all	O
MetaCyc	O
reaction	O
sets	O
linked	O
at	O
E	O
=	O
1	O
.	O
0	O
×	O
10	O
−	O
10	O
or	O
better	O
to	O
MDDR	O
,	O
with	O
each	O
reaction	O
linking	O
to	O
an	O
average	O
of	O
just	O
2	O
.	O
8	O
MDDR	O
drug	O
sets	O
.	O

These	O
results	O
indicate	O
broad	O
and	O
specific	O
coverage	O
of	O
metabolism	O
,	O
and	O
suggest	O
that	O
numerous	O
additional	O
enzyme	O
targets	O
may	O
be	O
accessible	O
by	O
the	O
method	O
presented	O
here	O
.	O

Conclusion	O

Using	O
the	O
SEA	O
method	O
,	O
we	O
have	O
shown	O
that	O
comparison	O
between	O
ligand	O
sets	O
representing	O
MDDR	O
drug	O
classes	O
and	O
ligand	O
sets	O
representing	O
the	O
substrates	O
and	O
products	O
of	O
metabolic	O
reactions	O
yields	O
statistically	O
significant	O
links	O
between	O
known	O
drugs	O
and	O
enzyme	O
targets	O
.	O

Because	O
the	O
method	O
is	O
based	O
on	O
chemical	O
similarity	O
and	O
requires	O
only	O
information	O
from	O
these	O
molecule	O
sets	O
rather	O
than	O
the	O
sequence	O
,	O
structure	O
or	O
physiochemistry	O
of	O
the	O
targets	O
,	O
this	O
ligand	O
-	O
based	O
approach	O
is	O
independent	O
from	O
,	O
and	O
complementary	O
to	O
,	O
protein	O
structure	O
and	O
sequence	O
based	O
methods	O
.	O

Our	O
results	O
also	O
suggest	O
the	O
potential	O
of	O
this	O
method	O
for	O
predicting	O
previously	O
unknown	O
interactions	O
between	O
drug	O
classes	O
and	O
metabolic	O
targets	O
,	O
recovering	O
routes	O
of	O
metabolism	O
and	O
toxicity	O
in	O
humans	B-OG
,	O
and	O
identifying	O
potential	O
drug	O
targets	O
(	O
as	O
well	O
as	O
challenges	O
for	O
target	O
discovery	O
)	O
in	O
emerging	O
pathogens	O
.	O

Thus	O
,	O
by	O
mapping	O
the	O
chemical	O
diversity	O
of	O
drugs	O
to	O
small	O
molecule	O
metabolism	O
using	O
ligand	O
topology	O
,	O
this	O
work	O
establishes	O
a	O
computational	O
framework	O
for	O
ligand	O
-	O
based	O
prediction	O
of	O
drug	O
class	O
action	O
,	O
metabolism	O
,	O
and	O
toxicity	O
.	O

Methods	O

Compound	O
sets	O

All	O
compounds	O
,	O
both	O
drugs	O
and	O
metabolites	O
,	O
are	O
represented	O
using	O
Daylight	O
SMILES	O
strings	O
[	O
29	O
].	O

Sets	O
comprised	O
of	O
isomers	O
with	O
unique	O
compound	O
names	O
were	O
retained	O
,	O
even	O
though	O
stereochemistry	O
was	O
later	O
removed	O
as	O
part	O
of	O
the	O
molecule	O
fingerprinting	O
process	O
.	O

Ligand	O
sets	O

Reaction	O
sets	O
were	O
extracted	O
from	O
the	O
8	O
.	O
15	O
.	O
2007	O
release	O
of	O
MetaCyc	O
based	O
upon	O
the	O
substrates	O
and	O
products	O
annotated	O
to	O
each	O
reaction	O
.	O

Two	O
filters	O
were	O
applied	O
.	O

First	O
,	O
the	O
ten	O
most	O
common	O
metabolites	O
based	O
on	O
the	O
number	O
of	O
occurrences	O
in	O
the	O
MetaCyc	O
metabolic	O
network	O
were	O
removed	O
:	O
water	O
,	O
ATP	O
,	O
ADP	O
,	O
NAD	O
,	O
pyrophosphate	O
,	O
NADH	O
,	O
carbon	O
dioxide	O
,	O
AMP	O
,	O
glutamate	O
,	O
and	O
pyruvate	O
.	O

Second	O
,	O
each	O
reaction	O
set	O
was	O
required	O
to	O
include	O
at	O
least	O
two	O
unique	O
compounds	O
,	O
as	O
indicated	O
by	O
a	O
MetaCyc	O
or	O
a	O
MDDR	O
unique	O
compound	O
id	O
.	O

Drug	O
sets	O

Drug	O
sets	O
were	O
extracted	O
from	O
the	O
MDDR	O
,	O
a	O
compilation	O
of	O
about	O
169	O
,	O
000	O
drug	O
-	O
like	O
ligands	O
in	O
688	O
activity	O
classes	O
,	O
each	O
targeting	O
a	O
specific	O
enzyme	O
(	O
designated	O
by	O
the	O
Enzyme	O
Commission	O
(	O
E	O
.	O
C	O
.)	O
number	O
).	O

The	O
subset	O
of	O
this	O
database	O
for	O
which	O
mappings	O
between	O
enzymes	O
and	O
the	O
MDDR	O
drug	O
classes	O
were	O
available	O
was	O
used	O
.	O

These	O
mappings	O
were	O
based	O
on	O
a	O
previous	O
study	O
that	O
maps	O
E	O
.	O
C	O
.	O
numbers	O
,	O
GPCRs	B-GP
,	O
ion	B-GP
channels	I-GP
and	O
nuclear	B-GP
receptors	I-GP
to	O
MDDR	O
activity	O
classes	O
[	O
32	O
].	O

Only	O
sets	O
containing	O
five	O
or	O
more	O
ligands	O
were	O
used	O
.	O

Salts	O
and	O
fragments	O
were	O
removed	O
,	O
ligand	O
protonation	O
was	O
normalized	O
and	O
duplicate	O
molecules	O
were	O
removed	O
.	O

Of	O
the	O
688	O
targets	O
in	O
the	O
MDDR	O
,	O
97	O
were	O
excluded	O
as	O
having	O
too	O
few	O
ligands	O
(<	O
5	O
),	O
and	O
another	O
345	O
targets	O
were	O
excluded	O
because	O
their	O
definitions	O
did	O
not	O
describe	O
a	O
molecular	O
target	O
,	O
e	O
.	O
g	O
.,	O
drugs	O
associated	O
only	O
with	O
an	O
annotation	O
such	O
as	O
“	O
Anticancer	O
”	O
were	O
not	O
used	O
.	O

The	O
remaining	O
246	O
enzyme	O
targets	O
were	O
together	O
associated	O
with	O
a	O
total	O
of	O
65	O
,	O
241	O
unique	O
ligands	O
,	O
with	O
a	O
median	O
and	O
mean	O
of	O
124	O
and	O
289	O
drug	O
ligands	O
per	O
target	O
.	O

For	O
further	O
details	O
,	O
see	O
Keiser	O
et	O
al	O
.	O
[	O
6	O
].	O

Set	O
comparisons	O

All	O
pairs	O
of	O
ligands	O
between	O
any	O
two	O
sets	O
were	O
compared	O
using	O
a	O
pair	O
-	O
wise	O
similarity	O
metric	O
,	O
which	O
consists	O
of	O
a	O
descriptor	O
and	O
a	O
similarity	O
criterion	O
.	O

For	O
the	O
similarity	O
descriptor	O
,	O
standard	O
two	O
-	O
dimensional	O
topological	O
fingerprints	O
were	O
computed	O
using	O
the	O
Scitegic	O
ECFP4	O
fingerprint	O
[	O
56	O
].	O

The	O
similarity	O
criterion	O
was	O
the	O
widely	O
used	O
Tanimoto	O
coefficient	O
(	O
Tc	O
)	O
[	O
57	O
].	O

For	O
set	O
comparisons	O
,	O
all	O
pair	O
-	O
wise	O
Tcs	O
between	O
elements	O
across	O
sets	O
were	O
calculated	O
,	O
and	O
those	O
scoring	O
above	O
a	O
threshold	O
were	O
summed	O
,	O
giving	O
a	O
raw	O
score	O
relating	O
the	O
two	O
sets	O
.	O

The	O
Tanimoto	O
coefficient	O
threshold	O
of	O
0	O
.	O
32	O
was	O
determined	O
according	O
to	O
a	O
previously	O
published	O
method	O
based	O
upon	O
fit	O
to	O
an	O
extreme	O
value	O
distribution	O
[	O
6	O
].	O

A	O
model	O
for	O
random	O
similarity	O
similar	O
to	O
that	O
used	O
by	O
BLAST	O
[	O
58	O
]	O
was	O
used	O
to	O
generate	O
expectation	O
values	O
(	O
E	O
)	O
which	O
are	O
used	O
to	O
describe	O
the	O
strengths	O
of	O
relationships	O
discovered	O
using	O
this	O
protocol	O
[	O
6	O
].	O

All	O
scores	O
reported	O
here	O
are	O
based	O
upon	O
the	O
background	O
distribution	O
and	O
cutoff	O
scores	O
generated	O
using	O
the	O
drug	O
sets	O
extracted	O
from	O
the	O
MDDR	O
collection	O
.	O

For	O
further	O
details	O
,	O
see	O
Keiser	O
et	O
al	O
.	O
[	O
6	O
].	O

Network	O
visualization	O
was	O
performed	O
in	O
Cytoscape	O
2	O
.	O
6	O
.	O
2	O
[	O
59	O
]	O
using	O
the	O
γ	O
-	O
files	O
hierarchical	O
layout	O
algorithm	O
.	O

MRSA	B-OG
essentiality	O
and	O
synthetic	O
lethal	O
analysis	O

Essentiality	O
and	O
synthetic	O
lethal	O
data	O
generated	O
as	O
described	O
earlier	O
[	O
48	O
].	O

Briefly	O
,	O
the	O
metabolic	O
network	O
was	O
reconstructed	O
from	O
the	O
genome	O
to	O
include	O
all	O
reactions	O
that	O
have	O
an	O
active	O
flux	O
The	O
essentiality	O
of	O
a	O
given	O
enzyme	O
was	O
then	O
assessed	O
by	O
the	O
effect	O
of	O
the	O
removal	O
of	O
that	O
enzyme	O
on	O
biomass	O
production	O
.	O

Similarly	O
,	O
synthetic	O
lethal	O
pairs	O
can	O
be	O
identified	O
by	O
systematic	O
pairwise	O
deletion	O
of	O
enzymes	O
and	O
recalculation	O
of	O
biomass	O
production	O
in	O
an	O
ideally	O
rich	O
medium	O
.	O

Supporting	O
Information	O

MetaCyc	O
reaction	O
sets	O

(	O
0	O
.	O
47	O
MB	O
TXT	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

SMILES	O
describing	O
the	O
molecular	O
strucutre	O
of	O
MetaCyc	O
reaction	O
substrates	O
and	O
products	O

(	O
0	O
.	O
25	O
MB	O
TXT	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

MDDR	O
drug	O
sets	O

(	O
0	O
.	O
51	O
MB	O
TXT	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

SMILES	O
describing	O
the	O
molecular	O
structure	O
of	O
MDDR	O
ligands	O
.	O

(	O
4	O
.	O
45	O
MB	O
TXT	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

E	O
-	O
values	O
for	O
links	O
between	O
MDDR	O
drug	O
sets	O
and	O
MetaCyc	O
reaction	O
sets	O

(	O
3	O
.	O
12	O
MB	O
CSV	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

